[177Lu]Lu-PSMA延长治疗的安全性与疗效:一项德国多中心研究
这项德国多中心回顾性分析纳入111例接受超过6周期[177Lu]Lu-PSMA放射药物治疗的转移性去势抵抗性前列腺癌患者,分为连续治疗组(43/111,38.7%)和再挑战组(68/111,61.3%)。全队列自首次给药起中位总生存为31.3个月,连续治疗组为23.2个月,再挑战组为40.2个月;两组3-4级毒性发生率相当。结论认为延长治疗安全,未伴3-4级毒性增加,再挑战后仍保持疗效。
要点
- 111例患者接受超过6周期[177Lu]Lu-PSMA延长治疗,连续治疗组与再挑战组的中位累积剂量分别为57.4 GBq和60.8 GBq。
- 全队列自首次[177Lu]Lu-PSMA给药起中位总生存为31.3个月,连续治疗组为23.2个月,再挑战组为40.2个月。
- 再挑战组首次50% PSA下降率高于连续治疗组(57/63 [90.4%] vs. 26/42 [61.9%],P=0.006),首次再挑战后50% PSA下降见于23/62例(37.1%)。
核心结论
- [177Lu]Lu-PSMA延长治疗是安全的,未伴3-4级毒性增加。
- 适合延长治疗的患者自首次给药起中位生存为31.3个月。
- [177Lu]Lu-PSMA再挑战在治疗间歇后仍显示保持的疗效。
研究设计与样本
- 德国多中心回顾性分析,纳入111例接受超过6周期[177Lu]Lu-PSMA放射药物治疗的患者。
- 根据个体化决策,患者接受不间断继续治疗(连续治疗)或治疗间歇后再次暴露(再挑战治疗),时间范围为2014年至2023年。
- 评估总生存、50%前列腺特异性抗原(PSA)下降(治疗开始或再挑战后8-12周测量)、PSMA PET缓解及常见不良事件术语标准分级。
- 统计方法采用χ2检验、多因素Cox回归分析和log-rank检验。
主要发现
- 连续治疗组43/111例(38.7%),再挑战组68/111例(61.3%),中位累积剂量分别为57.4 GBq和60.8 GBq。
- 自[177Lu]Lu-PSMA起始起中位总生存:全队列31.3个月,连续治疗组23.2个月,再挑战组40.2个月。
- 首次50% PSA下降率再挑战组高于连续治疗组(57/63 [90.4%] vs. 26/42 [61.9%],P=0.006)。
- 首次再挑战后50% PSA下降见于23/62例(37.1%)。
- 3-4级毒性发生率连续治疗组与再挑战组相当:贫血7/43(16.3%) vs. 13/68(19.1%),P=0.6;白细胞减少1/43(2.3%) vs. 2/67(3.0%),P=0.3;血小板减少3/43(7.0%) vs. 3/68(4.4%),P=0.3;肾脏毒性2/43(4.7%) vs. 5/68(7.4%),P=0.2。
关键数值与推荐
- 延长治疗定义为接受超过6周期[177Lu]Lu-PSMA放射药物治疗。
- 连续治疗为不间断继续治疗,再挑战治疗为治疗间歇后再次暴露。
- 50% PSA下降于治疗开始或再挑战后8-12周测量。
- 毒性按常见不良事件术语标准分级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prospective results have demonstrated favorable safety and efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [177Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles. Methods: In total, 111 patients were included in this multicenter retrospective analysis. Based on individual decisions, patients underwent uninterrupted continuation of therapy (continuous treatment) or reexposure after a therapy break (rechallenge treatment) between 2014 and 2023. Overall survival, 50% prostate-specific antigen (PSA) decline (measured 8-12 wk after treatment initiation or rechallenge), PSMA PET response, and grades per Common Terminology Criteria for Adverse Events were assessed. χ2 tests, multivariable Cox regression analysis, and log-rank tests were applied for statistical analyses. Results: Patients received extended treatment with [177Lu]Lu-PSMA, either as a continuous treatment (43/111, 38.7%) or as a rechallenge (68/111, 61.3%) treatment, with median cumulative doses of 57.4 or 60.8 GBq, respectively. Overall survival from the initiation of [177Lu]Lu-PSMA was 31.3, 23.2, and 40.2 mo for the entire cohort, the continuous treatment group, and the rechallenge treatment group, respectively. The initial 50% PSA decline was significantly higher in the retreated group than in the continuous group (57/63 [90.4%] vs. 26/42 [61.9%]; P = 0.006). A 50% PSA decline was observed in 23 of 62 patients (37.1%) after the first rechallenge. The rate of grades 3-4 toxicity was comparable between continuous and rechallenge treatments (anemia, 7/43 [16.3%] vs. 13/68 [19.1%)], P = 0.6; leukocytopenia, 1/43 [2.3%] vs. 2/67 [3.0%], P = 0.3; thrombocytopenia, 3/43 [7.0%] vs. 3/68 [4.4%], P = 0.3; renal, 2/43 [4.7%] vs. 5/68 [7.4%], P = 0.2). Conclusion: Extended therapy with [177Lu]Lu-PSMA is safe and has not been associated with increased grades 3-4 toxicity. Patient candidates for extended treatment experienced a favorable median survival of 31.3 mo from the first administration. Response under [177Lu]Lu-PSMA rechallenge demonstrated preserved efficacy of [177Lu]Lu-PSMA after a treatment break.
引用
- Seifert R, Telli T, Lapa C, et al. Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study. J Nucl Med. 2024. PMID: 38697669. doi:10.2967/jnumed.123.267321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。